Literature DB >> 26969633

Significance of apical cavity obliteration in apical hypertrophic cardiomyopathy.

Hyungseop Kim1, Jung-Ho Park1, Ki-Bum Won1, Hyuck-Jun Yoon1, Hyoung-Seob Park1, Yun-Kyeong Cho1, Chang-Wook Nam1, Seongwook Han1, Seung-Ho Hur1, Yoon-Nyun Kim1, Kwon-Bae Kim1.   

Abstract

OBJECTIVE: Apical hypertrophic cardiomyopathy (HCM) is characterised by apical systolic obliteration and is associated with atrial fibrillation (AF), stroke, heart failure (HF), and mortality. We investigated whether apical obliteration of the left ventricular (LV) cavity could have an unfavourable impact on the clinical course of apical HCM.
METHODS: 188 patients with apical HCM (114 males, median age 67 years) were identified retrospectively from January 2008 to December 2010. The rate of apical obliteration was defined as the net obliteration to end-diastolic apical cap thickness, and the ratio of obliteration to cavity was defined as the end-systolic obliteration to cavity height. Events were defined as a composite of new onset of AF, stroke, HF, and cardiovascular (CV) death.
RESULTS: There were 43 clinical events (19 AFs, 11 HFs, 9 strokes, and 4 deaths) during a follow-up of median 4.4 years. The events patients were older, had larger left atrial volume index (LAVI), lower late diastolic mitral annular tissue Doppler velocity (a'), and higher LV end-diastolic pressure (E/e'). They had greater apical thickness and obliteration, smaller systolic cavity height, higher rate of obliteration, and higher ratio of obliteration to cavity; events were significantly higher (54%) in the upper tertiles of the ratio of obliteration to cavity. Age, E/e', a', LAVI, apical thickness, rate of obliteration, and ratio of obliteration to cavity were associated with events. On multivariable analysis, the ratio of obliteration to cavity remained a significant predictor.
CONCLUSIONS: The ratio of obliteration to cavity could provide useful information to predict the occurrence of adverse events in apical HCM. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Year:  2016        PMID: 26969633     DOI: 10.1136/heartjnl-2015-309121

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  6 in total

Review 1.  Apical variant hypertrophic cardiomyopathy "multimodality imaging evaluation".

Authors:  Gary Huang; Shaimaa A Fadl; Stan Sukhotski; Manuela Matesan
Journal:  Int J Cardiovasc Imaging       Date:  2019-12-18       Impact factor: 2.357

2.  Novel Resectable Myocardial Model Using Hybrid Three-Dimensional Printing and Silicone Molding for Mock Myectomy for Apical Hypertrophic Cardiomyopathy.

Authors:  Wooil Kim; Minje Lim; You Joung Jang; Hyun Jung Koo; Joon Won Kang; Sung Ho Jung; Dong Hyun Yang
Journal:  Korean J Radiol       Date:  2021-04-01       Impact factor: 3.500

3.  Multimodality Imaging Demonstrating an Apical Variant Hypertrophic Cardiomyopathy in an Uncommon Pentad.

Authors:  Ayman R Fath; Clinton E Jokerst; Amro Aglan; Nawfal Mihyawi; Farouk Mookadam
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

4.  Apical Hypertrophic Cardiomyopathy: The Variant Less Known.

Authors:  Rebecca K Hughes; Kristopher D Knott; James Malcolmson; João B Augusto; Saidi A Mohiddin; Peter Kellman; James C Moon; Gabriella Captur
Journal:  J Am Heart Assoc       Date:  2020-02-28       Impact factor: 5.501

5.  Left ventricular cavity obliteration: Mechanism of the intracavitary gradient and differentiation from hypertrophic obstructive cardiomyopathy.

Authors:  Charles Pollick; Hezzy Shmueli; Nicolas Maalouf; Ronit H Zadikany
Journal:  Echocardiography       Date:  2020-05-22       Impact factor: 1.724

6.  Surgical management of diastolic heart failure after septal myectomy for obstructive hypertrophic cardiomyopathy.

Authors:  Daokun Sun; Hartzell V Schaff; Rick A Nishimura; Jeffrey B Geske; Joseph A Dearani; Steve R Ommen
Journal:  JTCVS Tech       Date:  2021-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.